CN201237593Y - Chemical luminescence immunity analysis reagent box for combined detection of multi-tumor marker - Google Patents
Chemical luminescence immunity analysis reagent box for combined detection of multi-tumor marker Download PDFInfo
- Publication number
- CN201237593Y CN201237593Y CN 200820079989 CN200820079989U CN201237593Y CN 201237593 Y CN201237593 Y CN 201237593Y CN 200820079989 CN200820079989 CN 200820079989 CN 200820079989 U CN200820079989 U CN 200820079989U CN 201237593 Y CN201237593 Y CN 201237593Y
- Authority
- CN
- China
- Prior art keywords
- monoclonal antibody
- chemical luminescence
- detection
- tumor
- reagent box
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
The utility model provides a chemiluminescence immunoassay kit for a joint detection of a plurality of tumor markers, which consists of opaque demountable micropore laths; response holes are arranged on each of the opaque demountable micropore laths. Corresponding antibody is enveloped on each response hole. The utility model is characterized in that each 12 holes are a response lath; each response lath is loaded with uniform antibody to detect the same tumor marker; 3-8 tumor markers can be jointly detected. The chemiluminescence immunoassay kit for a joint detection of a plurality of tumor markers can conveniently, fast, accurately and jointly detect a plurality of tumor markers, and lower the cost for simultaneously detecting a plurality of tumor markers.
Description
Technical field
The utility model provides a kind of chemical luminescence immune analysis reagent box of joint-detection kinds of tumors mark.
Background technology
Tumour is a class serious threat human life and healthy malignant disease, and The World Health Organization (WHO) announced annual newly-increased 1,000 ten thousand cases of cancers in the whole world in 2002, had 12% to die from cancer in the death toll in the world at present.Therefore, WHO points out to diagnose early and treats is one of effective means of antagonism cancer, and the early diagnosis of tumour is a key factor of its prognosis of decision.(Tumor marker TM) as an important indicator, is bringing into play more and more important effect to tumor markers in the middle of early diagnosis of tumor.TM is produced by tumor tissues, and being present in tumor tissues itself or secreting to blood or other body fluid or because of tumor tissues stimulates by the content of the host cell generation class material apparently higher than normal reference value.TM has certain application value aspect tumor treatment monitoring and the prognosis.The tumor markers of finding has had kind more than 100 at present, because in most cases the content of in-vivo tumour mark is all very low, general detection method is difficult to it is carried out quantitatively accurate.Past is mainly used radio immunoassay to the detection of tumor markers, and there are many shortcomings in this method, as complicated operation, measurement result instability, reagent holding time weak point, radioactive contamination, instrument costliness etc.Therefore, demand developing a kind of new detection method urgently TM in the blood is carried out accurate quantitative test.
The appearance of chemiluminescence immunoassay technology improves constantly detection specificity, and diagnosing tumor research is constantly to deeply development.Past mainly is that single tumor markers is detected, because there are certain difference in cross reaction and mark specificity, therefore is restricted in actual applications.In recent years, people detect simultaneously by multiple TM, and use in conjunction is in the hope of reaching the purpose of accurate diagnosing tumour.
Compare with traditional detection method, the utility model can carry out the detection of a plurality of indexs simultaneously to a sample; Have high sensitivity and reliability; The detection cost is low, is beneficial to large-scale promotion application.Reaction of the present utility model and traditional chemical luminescence method are almost the same, the opaque 96 hole microwell plates of the standard of application surface special processing are as matrix, guaranteed the convenience and the agility of reaction, general all models are washed the board-like chemiluminescence immune assay of plate machine or complete/semi-automatic system on the compatible market; Problems such as other too much hand-manipulated and complicated operation, repeatability based on the biochip reaction step of slide or film etc. is poor, homogeneity difference have been solved.
Summary of the invention
That the purpose of this utility model has provided is easy, fast, the chemical luminescence immune analysis reagent box of joint-detection kinds of tumors mark accurately.
The utility model is made up of the bracing frame of position, 96 hole and the dismountable opaque micropore lath that is placed on it, wherein, per 12 holes are a reaction bar, the identical antibody of each reaction bar load, detect same tumor markers, can joint-detection 3-8 kind tumor markers.
The well-designed 96 orifice plate chemical luminescence immune analysis reagent boxes of the utility model, highly sensitive and special, easy and simple to handle quick, can detect the content of 3-8 kind tumor markers at short notice simultaneously, expense is cheap, the complementary primary dcreening operation of kinds of tumors when being applicable to tumour people at highest risk or the health check-up of tumour hotspot.It has specificity height, accuracy height, sensitivity, easy advantage such as fast.The utility model is particularly suitable for tumour hospital and promotes the use of, for clinical diagnosis and research work provide a kind of very valuable detection means.
What kit of the present utility model was used is the enzymatic luminous substrate, by the chromogenic substrate in the light signal replacement enzyme-linked immuno assay that detects the luminous substrate generation, thereby have a specificity equal with enzyme-linked immuno assay, and sensitivity improves greatly, ratio Enzyme Linked Immunoadsorbent Assay sensitivity now improves about 10 times, and the kinds of tumors joint-detection has improved the specificity and the accuracy of diagnosing tumor, and the diagnosis that can be tumor disease provides more special, quick, reliable foundation.
Description of drawings
The structural representation of Fig. 1 the utility model embodiment 1,2.
The structural representation of Fig. 2 the utility model embodiment 3-8.
The structural representation of Fig. 3 the utility model embodiment 9,10.
Embodiment
The chemical luminescence immune analysis reagent box of embodiment 1 preparation joint-detection prostate cancer
One, enzyme labeling thing preparation
Sodium periodate oxidizing process mark prostate specific antigen (PSA), compound prostate specific antigen (cPSA), three kinds of monoclonal antibodies of free prostate gland specificity antigen (fPSA) with improvement.
The Tris of enzyme labeling thing diluent preparing weighing 12.12g, 5g BSA and 1mL Proclin 300 put into clean container well with the mentioned reagent weighing, add distilled water to 1L, the dissolving mixing.
Adopt the working concentration of three kinds of enzyme labeling things of chessboard experimental selection respectively.One bottle of each product packing is divided into and adorns three bottles.
Two, the preparation of the compound calibration object of tumor markers
With prostate specific antigen (PSA), cytokeratin 19 (Cyfra21-1), alpha-fetoprotein (AFP), carcinomebryonic antigen (CEA), neuronspecific enolase (NSE), tumor-associated antigen 19-9-9 (CA19-9), tumor associated antigen 153 (CA15-3), tumor-associated antigen 72-4-4 (CA72-4), tumor-associated antigen 125 (CA125), tumor-associated antigen 50 (CA50), gastrin-releasing peptide precursor (ProGRP), ferritin (Fer), tissue polypeptides specific antigen (TPS), the pure product of Monophosphoinositideproteoglycans proteoglycans-3 (GPC3) are mixed with the compound calibration object of tumor markers, packing is low, high two concentration, the 2mL/ bottle.
Three, the preparation of solid phase reaction bar
As shown in Figure 1, wrap PSA monoclonal antibody on the quilt in the reacting hole on reaction bar 1-3
Four, chemical luminous substrate liquid
A liquid is to add Tris and dense HCl in distilled water to be made into 0.1M pH be 8.5 Tris-HCl damping fluid, comprise the Luminol of 4.0mg/mL and 0.3mg/mL to iodophenol.
B liquid is to add trisodium citrate and citric acid in distilled water, is mixed with 0.1M pH value and is 4.6 citrate buffer solution, comprises the superoxol of 200mg/mL.
Five, 20 times of cleansing solutions
Weighing 9.9g NaH
2PO
42H
2O, the NaH of 56.0g
2PO
412H
2O, 116g NaCl add distilled water to 1L in clean container, the dissolving mixing is adjusted PH to 7.4.
Six, semi-manufacture and finished product are formed
The packing of above-mentioned steps products obtained therefrom is semi-manufacture.Extract three parts of chemical luminescence immune analysis reagent boxes that just can be assembled into the joint-detection prostate cancer through specificity, accuracy, sensitivity and stable assay approval out.Be assembled into and just can dispatch from the factory after needing behind the kit sampling observation qualified.
The chemical luminescence immune analysis reagent box of embodiment 2 preparation joint-detection colorectal cancers
Remove sodium periodate oxidizing process mark CEA with improvement, three kinds of monoclonal antibodies of CA19-9, CA72-4 as the enzyme labeling thing, as shown in Figure 1, in the reacting hole on reaction bar 1-3 successively respectively bag by on CEA monoclonal antibody, CA19-9 monoclonal antibody, CA72-4 monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The chemical luminescence immune analysis reagent box of embodiment 3 preparation joint-detection lung cancer
Remove sodium periodate oxidizing process mark Cyfra21-1 with improvement, NSE, CEA, four kinds of monoclonal antibodies of ProGRP as the enzyme labeling thing, as shown in Figure 2, in the reacting hole on reaction bar 1-4 successively respectively bag by on Cyfra21-1 monoclonal antibody, NSE monoclonal antibody, CEA monoclonal antibody, ProGRP monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The chemical luminescence immune analysis reagent box of embodiment 4 preparation joint-detection cancer of the stomach
Remove sodium periodate oxidizing process mark CEA with improvement, CA19-9, CA72-4, four kinds of monoclonal antibodies of Cyfra21-1 as the enzyme labeling thing, as shown in Figure 2, in the reacting hole on reaction bar 1-4 successively respectively bag by on CEA monoclonal antibody, CA19-9 monoclonal antibody, CA72-4 monoclonal antibody, Cyfra21-1 monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The chemical luminescence immune analysis reagent box of embodiment 5 preparation joint-detection liver cancer
Remove sodium periodate oxidizing process mark AFP with improvement, CA19-9, Fer, four kinds of monoclonal antibodies of GPC3 as the enzyme labeling thing, as shown in Figure 2, in the reacting hole on reaction bar 1-4 successively respectively bag by on AFP monoclonal antibody, CA19-9 monoclonal antibody, Fer monoclonal antibody, GPC3 monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The chemical luminescence immune analysis reagent box of embodiment 6 preparation joint-detection cancers of pancreas
Remove sodium periodate oxidizing process mark CEA with improvement, CA19-9, CA242, four kinds of monoclonal antibodies of CA50 as the enzyme labeling thing, as shown in Figure 2, in the reacting hole on reaction bar 1-4 successively respectively bag by on CEA monoclonal antibody, CA19-9 monoclonal antibody, CA242 monoclonal antibody, CA50 monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The chemical luminescence immune analysis reagent box of embodiment 7 preparation joint-detection oophoromas
Remove sodium periodate oxidizing process mark CA125 with improvement, CA153, CA72-4, four kinds of monoclonal antibodies of AFP as the enzyme labeling thing, as shown in Figure 2, in the reacting hole on reaction bar 1-4 successively respectively bag by on CA125 monoclonal antibody, CA153 monoclonal antibody, CA72-4 monoclonal antibody, AFP monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The chemical luminescence immune analysis reagent box of embodiment 8 preparation joint-detection breast cancer
Remove sodium periodate oxidizing process mark CA153 with improvement, CEA, CA72-4, four kinds of monoclonal antibodies of TPS as the enzyme labeling thing, as shown in Figure 2, in the reacting hole on reaction bar 1-4 successively respectively bag by on CA153 monoclonal antibody, CEA monoclonal antibody, CA72-4 monoclonal antibody, TPS monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The tumor markers chemical luminescence immune analysis reagent box that the embodiment 9 preparation joint-detection male sex 8
Remove sodium periodate oxidizing process mark Cyfra21-1 with improvement, AFP, CEA, NSE, CA19-9, PSA, CA72-4, eight kinds of monoclonal antibodies of CA125 as the enzyme labeling thing, as shown in Figure 3, in the reacting hole on reaction bar 1-8 successively respectively bag by on Cyfra21-1 monoclonal antibody, AFP monoclonal antibody, CEA monoclonal antibody, NSE monoclonal antibody, CA19-9 monoclonal antibody, PSA monoclonal antibody, CA72-4 monoclonal antibody, CA125 monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
The tumor markers chemical luminescence immune analysis reagent box that embodiment 10 preparation joint-detection women 8
Remove sodium periodate oxidizing process mark Cyfra21-1 with improvement, AFP, CEA, NSE, CA19-9, CA153, CA72-4, eight kinds of monoclonal antibodies of CA125 as the enzyme labeling thing, as shown in Figure 3, in the reacting hole on reaction bar 1-8 successively respectively bag by on Cyfra21-1 monoclonal antibody, AFP monoclonal antibody, CEA monoclonal antibody, NSE monoclonal antibody, CA19-9 monoclonal antibody, CA153 monoclonal antibody, CA72-4 monoclonal antibody, CA125 monoclonal anti external, all the other all prepare this kit with the method identical with embodiment 1.
Claims (1)
1, a kind of chemical luminescence immune analysis reagent box of joint-detection kinds of tumors mark, it is made up of the bracing frame of position, 96 hole and the dismountable opaque micropore lath that is placed on it, on each dismountable opaque reaction bar, reacting hole is set, on each reacting hole, be coated with corresponding antibody, it is characterized in that: per 12 holes are a reaction bar, the identical antibody of each reaction bar load.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200820079989 CN201237593Y (en) | 2008-04-16 | 2008-04-16 | Chemical luminescence immunity analysis reagent box for combined detection of multi-tumor marker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200820079989 CN201237593Y (en) | 2008-04-16 | 2008-04-16 | Chemical luminescence immunity analysis reagent box for combined detection of multi-tumor marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201237593Y true CN201237593Y (en) | 2009-05-13 |
Family
ID=40650326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200820079989 Expired - Fee Related CN201237593Y (en) | 2008-04-16 | 2008-04-16 | Chemical luminescence immunity analysis reagent box for combined detection of multi-tumor marker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201237593Y (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105372428A (en) * | 2015-12-08 | 2016-03-02 | 孙丽华 | Quantitative detection kit of carbohydrate chain antigen 125 |
-
2008
- 2008-04-16 CN CN 200820079989 patent/CN201237593Y/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105372428A (en) * | 2015-12-08 | 2016-03-02 | 孙丽华 | Quantitative detection kit of carbohydrate chain antigen 125 |
| CN105372428B (en) * | 2015-12-08 | 2016-08-24 | 陈立国 | The immue quantitative detection reagent box of CA125 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101750497A (en) | Enzymatic chemical luminous immunoassay quantitative determination reagent kit for simultaneously detecting various tumor markers | |
| CN102507947B (en) | CEA TRFIA (time-resolved fluoroimmunoassay) kit based on IMB (immunomagnetic beads) | |
| CN101603966A (en) | A kind of male multi-tumor marker detection protein chip and kit thereof | |
| CN101358976A (en) | Micro array-ELISA detecting kit for detecting six tumor markers | |
| CN101178405B (en) | Tumor-associated antigen 50 chemiluminescence immune analyze quantitative determination reagent box and method of producing the same | |
| CN104136630B (en) | Diagnosis and the mark of indication breast carcinoma | |
| CN101377500A (en) | Free prostate gland specificity antigen chemiluminescence immune analysis determination reagent kit and preparing method thereof | |
| CN201477101U (en) | Transferrin and hemoglobin combined detection board | |
| CN103018445B (en) | CA50 magnetic microparticle chemiluminescence immune quantitative detection reagent box and preparation method thereof | |
| CN106872434A (en) | A kind of portable pen type immunofluorescence chromatography detection means | |
| CN102279264A (en) | Preparation process for chip with 48 malignant tumor marker antibodies | |
| CN102103087A (en) | Carbohydrate antigen (CA) 125 chemiluminescent quantitative test kit | |
| CN201196651Y (en) | Gold mark detection test paper for double-tumor token | |
| CN101373188A (en) | Tumor-associated antigen 19-9 chemical luminescence immune analytic determination reagent kit and preparation method thereof | |
| CN1854736A (en) | Hepatitis B and C and multiple tumor marker protein chip inspecting reagent unit | |
| CN106442993A (en) | Preparation method of enzyme-linked immunosorbent assay kit for detecting ovarian cancer tumor marker CA125 based on trypsin fluorogenic substrate | |
| CN201237593Y (en) | Chemical luminescence immunity analysis reagent box for combined detection of multi-tumor marker | |
| CN101377498A (en) | Prostate gland specificity antigen chemiluminescence immune analysis determination reagent kit and preparing method thereof | |
| CN1987468B (en) | Time resolution fluorescence immune analysis method and kit for vascular endothelial growth factor | |
| CN109085359A (en) | Serum protein markers combine the application in colorectal cancer screening and diagnosis and treatment | |
| CN101545910A (en) | Ferritin chemoluminescence immunoassay quantitative measuring kit and preparation method thereof | |
| US10782288B2 (en) | Multi-unit for conducting biochemical test and immunological test and testing method thereof | |
| CN104597257A (en) | Rapid myoglobin detection method and corresponding detection kit | |
| CN103940817A (en) | Liquid sample collection detector filled with reagent | |
| CN103645320A (en) | Furaltadone metabolite chemiluminescent enzyme linked immune sorbent rapid analysis kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: BEIJING KEMEI BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: KEMEI DONGYA BIOLOGICAL TECHNOLOGY CO., LTD., BEIJING Effective date: 20110519 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110519 Address after: 100094 Beijing city Haidian District Yongfeng base Feng Xian Road No. 7 North Park Patentee after: Beijing Kemei Biological Technology Co., Ltd. Address before: 100094 Beijing city Haidian District Yongfeng base Feng Xian Road No. 7 North Park Patentee before: Kemei Dongya Biological Technology Co., Ltd., Beijing |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090513 Termination date: 20170416 |